LONG-TERM EXPERIENCE WITH SUMATRIPTAN IN THE TREATMENT OF MIGRAINE

被引:53
作者
TANSEY, MJB
PILGRIM, AJ
MARTIN, PM
机构
[1] GLAXO GRP RES LTD,CLIN & REGULATORY DIRECTORATE,CARDIOVASC GRP,GREENFORD UB6 0HE,MIDDX,ENGLAND
[2] GLAXO GRP RES LTD,INT MED AFFAIRS,CARDIOVASC & METAB MED,STOCKLEY PK,MIDDX,ENGLAND
关键词
SUMATRIPTAN; MIGRAINE;
D O I
10.1159/000116960
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Sumatriptan, a specific 5-hydroxytryptamine agonist, is a novel acute treatment for migraine. The efficacy and safety profiles of sumatriptan have previously been demonstrated in several controlled short-term studies. However, because migraine is a recurrent disorder which may persist throughout adult life, sustained efficacy and tolerability are essential if sumatriptan is to be of value in clinical practice. These aspects were therefore evaluated in a programme of three 12-month studies. Sustained efficacy with long-term use of single 100-mg oral doses has been demonstrated in an open study in which 288 patients treated 8,094 migraine attacks. The long-term safety profile of oral and subcutaneous sumatriptan has been evaluated in a total of 849 patients who treated 24,907 migraine attacks in studies lasting up to 1 year. Sumatriptan was well tolerated. Adverse events did not differ qualitatively or quantitatively from those in short-term studies, irrespective of the frequency of attacks or the number of doses used. Migraine attacks were effectively treated with doses less than the recommended maximum and there was no evidence of any adverse effect on attack frequency. In long-term studies the high efficacy of sumatriptan is maintained, and the adverse event profile is unchanged and unaffected by attack frequency.
引用
收藏
页码:310 / 315
页数:6
相关论文
共 18 条
  • [1] Blau JN, 1987, MIGRAINE CLIN THERAP, P3
  • [2] THE SAFETY AND TOLERABILITY OF SUMATRIPTAN - AN OVERVIEW
    BROWN, EG
    ENDERSBY, CA
    SMITH, RN
    TALBOT, JCC
    [J]. EUROPEAN NEUROLOGY, 1991, 31 (05) : 339 - 344
  • [3] BYER J, 1989, CEPHALALGIA S10, V9, P349
  • [4] DICHGANS J, 1988, ADV APPLIED NEUROL S, V5, P8
  • [5] THE CLINICAL-PHARMACOLOGY, PHARMACOKINETICS AND METABOLISM OF SUMATRIPTAN
    FOWLER, PA
    LACEY, LF
    THOMAS, M
    KEENE, ON
    TANNER, RJN
    BABER, NS
    [J]. EUROPEAN NEUROLOGY, 1991, 31 (05) : 291 - 294
  • [6] Goldstein M, 1982, Adv Neurol, V33, P377
  • [7] HOKKANEN E, 1987, HEADACHE, V18, P95
  • [8] LIPPMAN CARO W., 1955, JOUR NERV AND MENTAL DIS, V121, P270, DOI 10.1097/00005053-195503000-00012
  • [9] TRANSFORMATION OF EPISODIC MIGRAINE INTO DAILY HEADACHE - ANALYSIS OF FACTORS
    MATHEW, NT
    STUBITS, E
    NIGAM, MP
    [J]. HEADACHE, 1982, 22 (02): : 66 - 68
  • [10] PEATFIELD RC, 1986, HDB CLIN NEUROLOGY, V4, P173